Eckert & Ziegler BEBIG, Mick Radio-Nuclear Instruments, WOLF-Medizintechnik (WOmed)

Press Releases

We are keeping you informed! If you have questions regarding our press releases, feel free to contact us via the website´s contact form. Stay up-to-date with our companies latest news:

First SagiNova® HDR afterloader entered into operation in Turkey

Seneffe, Belgium, September 26, 2016, Eckert & Ziegler BEBIG announces its first SagiNova® installation in Turkey. The device was acquired by the Sante Oncology Center in Istanbul in exchange for its GyneSource afterloader which has been in use since 2008.

The Sante Oncology Center is part of the Sante Health Service, with over 30 years' experience in radiotherapy. The hospital can treat up to 150 new patients a month and aims to be a fully equipped diagnostics and oncology treatment center. "Our aspiration is to treat our patients with the latest state-of-the-art medical equipment in order to ensure effective and efficient outcomes. We have been very satisfied with our cobalt-60 GyneSource which we have used especially for treating uterine and cervical cancer. Updating to SagiNova® gives us the opportunity to expand our brachytherapy services to other body areas in the future", says Mr. Baki Temel, CEO of the Sante Oncology Center.

As with GyneSource, the new SagiNova® is equipped with a long-lasting cobalt-60 source, providing a certified 100,000 source transfer. "We found cobalt-60 to be an effective solution for our needs. Along with the integrated In-Vivo Dosimetry System, SagiNova® is a safe and sophisticated brachytherapy afterloader, especially for the treatment of gynecological cancers", adds Mr. Temel.

Sante received its SagiNova® in March. Shortly after the delivery of SagiNova®, physician and physicist trainings were carried out by the Eckert & Ziegler BEBIG Application Service and Support, enabling a seamless transition from the old to the new afterloader.

About High Dose Rate (HDR) Brachytherapy
HDR brachytherapy allows radiation oncologists to deliver the radiation quickly, most often as an outpatient procedure. During this procedure a computer driven apparatus, called a remote afterloading device, pushes the radioactive source attached to a drive wire through transfer tubes and applicators to the treatment site. The radioactive source can be moved in millimeter increments and remain in a certain position (dwell position) for a predetermined amount of time to optimize the dose delivered. When the desired treatment dose has been achieved, the remote afterloading device automatically withdraws the radioactive source so there is no residual radiation or radioactivity.
HDR brachytherapy has been used since the 1960s and today is applied to treat cancers in body sites such as gynecological, rectal, prostate and breast. The procedure enables an accurate and precise tumor-specific radiation dose delivery in a shorter course of treatment compared to other types of radiation treatment modalities while preserving the structure and function of the organ(s) treated and nearby.

About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treat­ment of cancer using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and in the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 130 people. The company has been listed on the Euronext stock exchange since April 1997.

Annica Witt
Marketing Communication Manager